Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia

New England Journal of Medicine

Volumn 336, Issue 5, 1997, Pages 317-323

  Roberts, William Mark ^a   Estrov, Zeev ^b   Ouspenskaia, Maia V ^a   Johnston, Dennis A ^a   Mcclain, Kenneth L ^c   Zipf, Theodore F ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CELL DNA; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HYDROCORTISONE; IMMUNOGLOBULIN HEAVY CHAIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CLONOGENIC ASSAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; INTRATHECAL DRUG ADMINISTRATION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

BONE MARROW; CHILD; CLONE CELLS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS;

EID: 0031016326     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199701303360501     Document Type: Article

References (29)

1. George SL, Aur RJA, Mauer AM, Simone JV. A reappraisal of the results of stopping therapy in childhood leukemia. N Engl J Med 1979;300:269-73.
2. Estrov Z, Grunberger T, Dubé ID, Wang Y-P, Freedman MH. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med 1986;315:538-42.
3. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G. Minimal residual disease in childhood B-lineage lymphoblastic leukemia: persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 1990;323:448-55.
4. Nizet Y, Martiat P, Vaerman JL, et al. Follow-up of residual disease (MRD) in B lineage acute leukemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome. Br J Haematol 1991;79:205-10.
5. Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TF. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia 1995;9:321-8.
6. Estrov Z, Ouspenskaia MV, Felix EA, et al. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia 1994;8:46-52.
7. Pinkel D, Lockhart S, Mullins J, Ramirez I, Zipf T. Species-specific therapy of childhood acute lymphoid leukemia. Proc Am Assoc Cancer Res 1992;33:211. abstract.
8. Bennett JM, Catovsky D, Daniel MT, et al. The morphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlations. Br J Haematol 1981;47:553-61.
9. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339:237-8. [Erratum, Nature 1989;339:490.]
10. Deane M, Norton JD. Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B lineage leukemias. Eur J Immunol 1990;20:2209-17.
11. Roberts WM, Zipf TF, Kitchingman GR, Tubergen DG, Estrov Z. Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications. Cytokines Mol Ther 1995;1:65-9.
12. Shahangian S, Fritsche HA Jr, Hughes JI, Johnston DA. Methods for determining "reference changes" from serial measurements: plasma lipid-bound sialic acid. Clin Chem 1989;35:972-4.
13. Smith MS, Arthur DA, Camitta BC, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
14. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Leuk Lymphoma 1996;20:181-97.
15. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85: 1416-34.
16. Ito Y, Wasserman R, Galili N, et al. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J Clin Oncol 1993;11:546-53.
17. Bartram CR. Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy. Clin Chim Acta 1993;217:75-83.
18. Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol 1993;83:412-8.
19. Pui C-H, Dodge RK, Look AT, et al. Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St Jude total therapy studies VIII, IX, X. J Clin Oncol 1991;9:1341-7.
20. Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964; 35:1-111.
21. Ito Y, Miyamura K. Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure? Leuk Lymphoma 1994;16:57-64.
22. Nizet Y, Van Daele S, Lewalle P, et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 1993;82:1618-25.
23. Wu N-H, Lu S-G, Zhu P, Peng Y-Y. Detection of minimal residual disease in childhood acute lymphoblastic leukemia after termination of therapy. Pediatr Hematol Oncol 1996;13:257-63.
24. Chang K-S, Fan Y-H, Stass SA, et al. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene 1993;8:983-8.
25. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993;82:712-5.
26. Jurlander J, Caligiuri M, Ruutu T, et al. Persistence of the AML/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996;88:2183-91.
27. Gale RP, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet 1991;338:1315-8.
28. Bradstock KF, Gottlieb DJ. Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk Lymphoma 1995;18:1-16.
29. Montagna D, Arico M, Montini E, De Benedetti F, Maccario R. Identification of HLA-unrestricted CD8+/CD28- cytotoxic T-cell clones specific for leukemic blasts in children with acute leukemia. Cancer Res 1995; 55:3835-9.